HC Wainwright Analysts Lower Earnings Estimates for NBIX

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Research analysts at HC Wainwright decreased their Q4 2025 earnings estimates for shares of Neurocrine Biosciences in a research report issued on Friday, February 21st. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of $1.06 per share for the quarter, down from their previous forecast of $1.20. HC Wainwright has a “Buy” rating and a $185.00 price objective on the stock. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.28 per share. HC Wainwright also issued estimates for Neurocrine Biosciences’ FY2026 earnings at $4.43 EPS, FY2027 earnings at $7.33 EPS and FY2029 earnings at $14.69 EPS.

A number of other equities analysts also recently weighed in on NBIX. Piper Sandler reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Neurocrine Biosciences in a research note on Monday, December 23rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Neurocrine Biosciences in a research note on Friday, February 7th. Guggenheim decreased their price objective on shares of Neurocrine Biosciences from $165.00 to $163.00 and set a “buy” rating for the company in a report on Monday, February 10th. Royal Bank of Canada decreased their price objective on shares of Neurocrine Biosciences from $154.00 to $148.00 and set a “sector perform” rating for the company in a report on Friday, February 7th. Finally, William Blair reiterated an “outperform” rating on shares of Neurocrine Biosciences in a report on Friday, February 7th. Five analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $166.90.

Neurocrine Biosciences Trading Up 3.9 %

NASDAQ NBIX opened at $120.69 on Monday. Neurocrine Biosciences has a 1-year low of $110.95 and a 1-year high of $157.98. The company has a market capitalization of $12.03 billion, a PE ratio of 36.68, a price-to-earnings-growth ratio of 0.77 and a beta of 0.33. The firm’s fifty day simple moving average is $136.63 and its 200-day simple moving average is $129.31.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%.

Neurocrine Biosciences declared that its Board of Directors has approved a share repurchase plan on Friday, February 21st that permits the company to repurchase $500.00 million in shares. This repurchase authorization permits the company to buy up to 4.2% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Insider Activity

In related news, CEO Kyle Gano sold 65,000 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $141.50, for a total value of $9,197,500.00. Following the completion of the transaction, the chief executive officer now owns 135,392 shares of the company’s stock, valued at $19,157,968. This represents a 32.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Kevin Charles Gorman sold 5,844 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $116.69, for a total transaction of $681,936.36. Following the sale, the director now directly owns 521,618 shares of the company’s stock, valued at approximately $60,867,604.42. The trade was a 1.11 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 236,600 shares of company stock valued at $34,348,261. Insiders own 4.30% of the company’s stock.

Institutional Trading of Neurocrine Biosciences

Hedge funds have recently modified their holdings of the stock. Caprock Group LLC bought a new position in shares of Neurocrine Biosciences during the fourth quarter worth $236,000. Plato Investment Management Ltd increased its stake in Neurocrine Biosciences by 2,481.9% in the 3rd quarter. Plato Investment Management Ltd now owns 10,973 shares of the company’s stock valued at $1,263,000 after buying an additional 10,548 shares during the last quarter. Swiss National Bank increased its stake in Neurocrine Biosciences by 1.4% in the 3rd quarter. Swiss National Bank now owns 298,700 shares of the company’s stock valued at $34,416,000 after buying an additional 4,100 shares during the last quarter. Tri Ri Asset Management Corp bought a new position in shares of Neurocrine Biosciences in the 3rd quarter valued at about $3,236,000. Finally, KBC Group NV grew its position in shares of Neurocrine Biosciences by 78.3% in the 3rd quarter. KBC Group NV now owns 18,972 shares of the company’s stock valued at $2,186,000 after acquiring an additional 8,332 shares during the period. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.